Relevant bibliographies by topics / Vaccine development

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers
  6. Reports

Academic literature on the topic 'Vaccine development'

Author: Grafiati
Published: 4 June 2021
Last updated: 15 June 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Vaccine development.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Vaccine development"

1

Alexander, NJ, and G. Bialy. "Contraceptive vaccine development." Reproduction, Fertility and Development 6, no. 3 (1994): 273. http://dx.doi.org/10.1071/rd9940273.

Full text
Abstract:
Recent advances in antigen definition and production have made the development of a contraceptive vaccine more attainable. Such a vaccine must evoke an immune response that blocks an indispensable step in the reproductive process. Vaccine research involves many approaches to fertility prevention. Vaccines are being developed that could interrupt fertility by inhibition of gonadotrophin release, the function of follicle-stimulating hormone or the effects of human chorionic gonadotrophin (hCG); alternatively, they may prevent fertilization by interfering with the transport of spermatozoa or with sperm-zona pellucida binding. The most advanced prototype is a vaccine based on antibodies to beta hCG. Such vaccines are being studied for clinical efficacy. Many hurdles remain in contraceptive vaccine development. Since the antigens are peptides or small proteins, the resultant immune response is usually moderate, and better adjuvants and delivery systems must be developed to enhance and maintain the immune response. Improvement of the mucosal immune response may be necessary for vaccines incorporating sperm antigens. Research on vaccines that control fertility has resulted in a fascinating base of scientific knowledge that, it is hoped, can be converted into products that will allow another option for individuals who wish to control their fertility.
APA, Harvard, Vancouver, ISO, and other styles
2

Mastroeni,, Pietro, and Nathalie Ménager. "Development of acquired immunity to Salmonella." Journal of Medical Microbiology 52, no. 6 (2003): 453–59. http://dx.doi.org/10.1099/jmm.0.05173-0.

Full text
Abstract:
Salmonella enterica serovar Typhi (S. typhi) causes human typhoid fever, a serious and widespread disease in developing countries. Other Salmonella serovars are associated with food-borne infections. The recent emergence of multi-drug-resistant Salmonella strains highlights the need for better preventive measures, including vaccination. The available vaccines against Salmonella infection do not confer optimal protection. The design of new Salmonella vaccines must be based on the identification of suitable virulence genes and on knowledge of the immunological mechanisms of resistance to the disease. Control and clearance of a vaccine strain rely on the phagocyte oxidative burst, reactive nitrogen intermediates, inflammatory cytokines and CD4+ TCR-αβ+ T cells and are controlled by genes including NRAMP1 and MHC class II. Vaccine-induced resistance to reinfection requires the presence of Th1-type immunological memory and anti-Salmonella antibodies. The interaction between T and B cells is essential for the development of resistance following vaccination. The identification of immunodeficiencies that render individuals more susceptible to salmonellosis must be taken into consideration when designing and testing live attenuated Salmonella vaccines. An ideal live Salmonella vaccine should therefore be safe, regardless of the immunological status of the vaccinee, but still immunogenic.
APA, Harvard, Vancouver, ISO, and other styles
3

Xia, Yueting. "New Development of Vaccine Technology in Tumor Therapy." Theoretical and Natural Science 59, no. 1 (2024): 269–76. http://dx.doi.org/10.54254/2753-8818/59/20241442.

Full text
Abstract:
Abstract. Cancer vaccines are a crucial component of tumors immunotherapy, offering the advantage of minimizing adverse reactions to induce tumor regression. They also enable the establishment of lasting anti-tumor memory. Recent years have seen significant breakthroughs in cancer vaccines, including the customization of personalized vaccines and the transition from passive immunization to active treatment. Currently, most cancer vaccine future goals focus on improving cost and efficiency such as combining immunology and bioinformatics to predict more accurate vaccine epitopes. This paper focuses on three innovative technologies in therapeutic cancer vaccines: cell vaccine, peptide cancer vaccine and nucleic acid cancer vaccine. This paper summarizes new selection of antigen-presenting cells for autologous tumor cell vaccine and allogeneic tumor cell vaccine, new research on adjuvants of peptide cancer vaccines and new nucleic acid cancer vaccine delivery platform. In addition, the combination of therapeutic vaccines is briefly discussed. These new technologies offer cancer patients new treatment options and hope.
APA, Harvard, Vancouver, ISO, and other styles
4

Deng, Sheng-Qun, Xian Yang, Yong Wei, Jia-Ting Chen, Xiao-Jun Wang, and Hong-Juan Peng. "A Review on Dengue Vaccine Development." Vaccines 8, no. 1 (2020): 63. http://dx.doi.org/10.3390/vaccines8010063.

Full text
Abstract:
Dengue virus (DENV) has become a global health threat with about half of the world’s population at risk of infection. Although the disease caused by DENV is self-limiting in the first infection, the antibody-dependent enhancement (ADE) effect increases the mortality in the second infection with a heterotypic virus. Since there is no specific efficient medicine in treatment, it is urgent to develop vaccines to prevent infection and disease progression. Currently, only a live attenuated vaccine, chimeric yellow fever 17D—tetravalent dengue vaccine (CYD-TDV), has been licensed for clinical use in some countries, and many candidate vaccines are still under research and development. This review discusses the progress, strengths, and weaknesses of the five types of vaccines including live attenuated vaccine, inactivated virus vaccine, recombinant subunit vaccine, viral vectored vaccine, and DNA vaccine.
APA, Harvard, Vancouver, ISO, and other styles
5

Titanji, Vincent P. K. "New approaches to vaccines for endemic and pandemic diseases of Africa with particular focus on building local competencies in Cameroon." Journal of the Cameroon Academy of Sciences 17, no. 1 (2021): 75–83. http://dx.doi.org/10.4314/jcas.v17i1.6.

Full text
Abstract:
Vaccines have been recognized as major and effective tools for the control and eventual elimination of infectious diseases and cancer. This brief review examines vaccine classification and development pipeline as well as recent innovations driving the vaccine development process. Using COVID-19 as an example recent innovation in vaccine development are highlighted. The review ends with a call for intensified efforts to build vaccine production capacity in Cameroon and other other African countries.
 Les vaccins ont été reconnus comme des outils majeurs et efficaces pour le contrôle et l’élimination éventuelle des maladies infectieuses et du cancer. Cette brève revue examine la classification et le pipeline de développement de vaccins ainsi que les innovations récentes à l’origine du processus de développement de vaccins. En utilisant COVID-19 comme exemple, les innovations récentes dans le développement de vaccins sont mises en évidence. La revue se termine par un appel à intensifier les efforts pour renforcer les capacités de production de vaccins au Cameroun et dans d’autres pays africains.
APA, Harvard, Vancouver, ISO, and other styles
6

Aljohani, Salwa, Waleed M. Hussein, Istvan Toth, and Pavla Simerska. "Carbohydrates in Vaccine Development." Current Drug Delivery 16, no. 7 (2019): 609–17. http://dx.doi.org/10.2174/1567201816666190702153612.

Full text
Abstract:
Despite advances in the development of new vaccines, there are still some diseases with no vaccine solutions. Therefore, further efforts are required to more comprehensively discern the different antigenic components of these microorganisms on a molecular level. This review summarizes advancement in the development of new carbohydrate-based vaccines. Following traditional vaccine counterparts, the carbohydrate-based vaccines introduced a new approach in fighting infectious diseases. Carbohydrates have played various roles in the development of carbohydrate-based vaccines, which are described in this review, including carbohydrates acting as antigens, carriers or targeting moieties. Carbohydrate-based vaccines against infectious diseases, such as group A streptococcus, meningococcal meningitis and human immunodeficiency virus, are also discussed. A number of carbohydrate- based vaccines, such as Pneumovax 23, Menveo and Pentacel, have been successfully marketed in the past few years and there is a promising standpoint for many more to come in the near future.
APA, Harvard, Vancouver, ISO, and other styles
7

AM, Aga. "Recent Advances in mRNA Vaccine Development." Open Access Journal of Microbiology & Biotechnology 8, no. 4 (2023): 1–17. http://dx.doi.org/10.23880/oajmb-16000275.

Full text
Abstract:
Messenger RNA vaccines are vaccine that utilizes a small segment of genetic material, messenger RNA (mRNA), to provide instructions to cells to produce a specific protein. This mRNA is synthesized in a laboratory and packaged into lipid nanoparticles, which protect and facilitate its entry into cells for protein synthesis. Upon injection into the muscle of the recipient, the mRNA instructs cells to produce a protein that is displayed on the surface of the cell, triggering an immune response. The immune system then produces antibodies and activates immune cells to target and eliminate the protein, while also generating memory cells to respond quickly in the event of future pathogen encounters. Available mRNA vaccines, such as Pfizer-BioNTech and Moderna, were developed and authorized for emergency use within a year. These vaccines require extensive cold chain storage, antigen delivery, potential immune response variability optimization, and sophisticated manufacturing process. To improve their effectiveness, stability, and delivery, efforts are underway to explore next-generation mRNA vaccines. Research is focused on enhancing the stability of mRNA vaccines, particularly their temperature sensitivity, to facilitate easier storage and distribution. Self-amplifying mRNA vaccines are also being developed to generate multiple copies of mRNA within cells, potentially leading to a higher production of protein and a stronger immune response. Studies are also exploring new delivery systems using specialized nanoparticles and liposomes to specifically target certain immune cells. Additionally, the development of combination vaccines, including multiple mRNA sequences in single vaccine, is being investigated to protect against multiple strains or variants of particular pathogen simultaneously. Direct delivery of mRNA vaccines into the skin is being explored as a means of enhancing immune response and reducing the required vaccine dose. In summary, messenger RNA vaccines represent a promising new approach to vaccination, with ongoing research aimed at improving their effectiveness, stability, and delivery
APA, Harvard, Vancouver, ISO, and other styles
8

Suo, Zhaotaize. "Universal Vaccine Development Against COVID-19 and Influenza." E3S Web of Conferences 553 (2024): 05044. http://dx.doi.org/10.1051/e3sconf/202455305044.

Full text
Abstract:
Universal vaccines appeared as a favorable solution for the rapid mutation of viruses that cause pandemics. Sufficient immune protection, safe and efficient production methods, and low-cost funding are ideal properties for universal vaccines. Targeting conserved regions, use of adjuvants, cell-mediated immunity approaches, virus-like particles, and multimeric presentation of viral antigens are strategies to enhance vaccine Immunogenicity. Different types of vaccines have been put into clinical trials, such as messenger RNA vaccines, on-replicating viral vector vaccines, and recombinant protein-based vaccines, which are proven to suit the needs of universal vaccine investigation. Moreover, this article introduces the universal vaccine development of SARS-CoV-2 and influenza variants, their vaccine candidates, research results, and the challenges faced. Universal vaccines are the trend of future viral protection, with more and more new technologies entering the field, a universal vaccine is within reach.
APA, Harvard, Vancouver, ISO, and other styles
9

Mboup, Elhadji Birane, Marie-Ève Hamelin, Julia Dubois, Manuel Rosa-Calatrava, and Guy Boivin. "Vaccine Development for Human Pneumoviruses." Vaccines 13, no. 6 (2025): 569. https://doi.org/10.3390/vaccines13060569.

Full text
Abstract:
Background: Pneumoviruses are etiologic agents of respiratory tract infections and a major cause of morbidity and mortality worldwide, particularly affecting young children, the elderly, and individuals with underlying clinical conditions. These viruses are associated with a significant burden, particularly in low- and middle-income countries, where reported deaths attributable to respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) in young children are important. Recent developments have been noted in the prevention of pneumoviral infections. Method: In this review, we analyzed clinical trials of the approved RSV vaccines, as well as the recent prominent platform technologies used in RSV vaccine research. In addition, we discussed combination vaccines targeting RSV, HMPV, and Human Parainfluenza Virus Type 3 (HPIV3) that have entered clinical trials. Results: Recent advancements include the approval of three RSV vaccine candidates: AREXVY®(GSK), ABRYSVO®(Pfizer), and mRESVIA®(Moderna). These vaccines are primarily intended for older adults, with ABRYSVO® also capable of providing passive immunization to infants via maternal administration. The review highlights RSV vaccine platform technologies and combination vaccines currently being evaluated in clinical settings. Conclusions: While significant progress has been made in RSV vaccine development, especially with three approved candidates, the development of vaccines for HMPV remains an unmet medical need. Ongoing research in combination vaccines holds promise for broader protection against multiple respiratory viruses in the future.
APA, Harvard, Vancouver, ISO, and other styles
10

Etefia, Etefia, and Paul Inyang Etoh. "Malaria Vaccine Development: Challenges and Prospects." Medical and Pharmaceutical Journal 2, no. 1 (2023): 28–42. http://dx.doi.org/10.55940/medphar202225.

Full text
Abstract:
Background: The development of a licensed malaria vaccine has been challenging due to the complex multi-stage life cycle, antigenic variation, and genetic diversity of Plasmodium. Numerous vaccines have been developed for various stages of Plasmodium, including pre-erythrocytic, blood stage, placenta, and transmission-blocking vaccines. However, none of these vaccines are completely effective and have high reactogenicity.Aim: The aim of this review is to examine the challenges and prospects in developing an effective malaria vaccine, with a focus on the development of a multi-stage or multivalent malaria vaccine.Materials and Methods: The authors conducted a review of the literature on malaria vaccine development, focusing on the challenges and prospects of developing an effective malaria vaccine.Results: Efforts are underway to develop a multi-stage or multivalent malaria vaccine (MultiMalVax) that may best target sporozoite development and neutralize merozoites, hepatocytes, and erythrocytes. A thorough understanding of potential vaccine targets and how immunity works is critical to developing a fully effective malaria vaccine.Conclusion: The challenges associated with developing an effective malaria vaccine are significant due to the complex nature of the Plasmodium life cycle. However, the development of a multi-stage or multivalent malaria vaccine offers prospects for overcoming these challenges and developing a fully effective malaria vaccine. A better understanding of potential vaccine targets and how immunity works is crucial in developing an effective vaccine against malaria.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Vaccine development"

1

Da, Silva Pissarra Joana. "Development of a multi-epitope peptide vaccine against human leishmaniases." Thesis, Montpellier, 2019. http://www.theses.fr/2019MONTT013/document.

Full text
Abstract:
La leishmaniose est une maladie tropicale négligée à transmission vectorielle qui est endémique dans 98 pays dont les plus pauvres. Vingt espèces de Leishmania sont capables d’établir une infection intracellulaire au sein des macrophages humains, provoquant différentes manifestations cliniques. Le développement d'un vaccin contre les leishmanioses est étayé par des preuves d'immunité naturelle contre l'infection, induite par une réponse à médiation cellulaire de type Th1 dominante associée à la production d'IFN-γ, d'IL-2 et de TNF-α par des cellules T polyfonctionnelles TCD4+ et TCD8+, conduisant à l'activation classique des macrophages entrainant la destruction des parasites. Induire une protection robuste et durable et déterminer les épitopes immunodominants responsables de la protection naturelle représente un véritable défi.Les protéines sécrétées sont des facteurs de virulence jouant un rôle important dans le cycle de vie des leishmanies et sont capables d’induire une protection durable chez le chien, un bon modèle pour l’infection humaine. Notre objectif est de développer, à partir du sécrétome de Leishmania, un vaccin de seconde génération reproductible et facile à produire à bas prix dans les zones d’endémie, avec des rendements de production rendant possible son utilisation à grande échelle.Les sécrétomes des six espèces les plus pathogènes de leishmanie (plus L. tarentolae) ont été analysés et comparées par spectrométrie de masse. Les antigènes candidats ont été recherchés dans l'ensemble des données disponibles (analyses protéomiques, littérature…). 52 antigènes candidats vaccin ont ainsi été sélectionnés, dont 28 avaient déjà été décrits et 24 sont nouveaux et découverts grâce à une approche de vaccinologie réverse.Une analyse de la prédiction de liaison des épitopes in silico HLA-I et –II a été réalisée sur tous les antigènes candidats vaccin, prenant ainsi en compte le polymorphisme HLA de la population mondiale. Pour sélectionner les meilleurs épitopes parmi des milliers d’épitopes potentiels, un script R automatisé a été développé en interne, selon des critères rationnels stricts. Ainsi, 50 épitopes de classe I et 24 épitopes de classe II ont été sélectionnés et synthétisés sous forme de peptides individuels. Des essais de toxicité in vitro ont montré l’absence de toxicité cellulaire de ces peptides.Les individus guéris par chimiothérapie généralement développent des réponses immunitaires protectrices à Leishmania. Des tests de stimulation des PBMC ont donc été réalisés avec des échantillons biologiques provenant de donneurs guéris de Tunisie et la production d'IFN-γ a été évaluée par ELISpot. De plus, il était important d'inclure dans l'étape de validation expérimentale des peptides des échantillons provenant d’individus naïfs, population cible à vacciner avec un vaccin prophylactique. Les résultats montrent que des peptides spécifiques de Leishmania induisent avec succès la production d'IFN-γ par les PBMC totaux provenant de donneurs guéris et par les lymphocytes T spécifiques amplifiés à partir du répertoire naïf.Globalement, la validation expérimentale des peptides réalisée exclusivement sur des échantillons humains nous fournira une base préclinique très solide pour développer un vaccin efficace capable de protéger les populations touchées par ces maladies. Elle constituera un moyen sûr et rentable de mieux sélectionner les candidats retenus pour le vaccin et d'éliminer ceux qui présentent un risque d'échec élevé au tout début du processus de développement du vaccin.Grâce à la combinaison de l'analyse protéomique et d'outils in silico, des candidats peptidiques prometteurs ont été rapidement identifiés pour le développement d'un vaccin. Le « pipeline » de développement préclinique du vaccin proposé fournit une sélection rapide de peptides immunogènes, offrant une approche puissante pour accélérer le déploiement d'un vaccin pan-spécifique efficace contre les leishmanioses<br>Leishmaniasis is a vector-borne neglected tropical disease endemic to 98 countries worldwide. Twenty Leishmania species are capable of establishing intracellular infection within human macrophages, causing different clinical presentations. Vaccine development against leishmaniases is supported by evidence of natural immunity against infection, mediated by a dominant cellular Th1 response and production of IFN-γ, IL-2 and TNF-α by polyfunctional TCD4+ and TCD8+ cells, ultimately leading to macrophage activation and parasite killing.Excreted-secreted proteins are important virulence factors present throughout Leishmania life stages and are able to induce durable protection in dogs, a good model for human infection. We aim to develop a second generation vaccine from the Leishmania secretome, with the potential for large scale dissemination in a cost-effective, reproducible approach.The secretome of six main pathogenic species (plus L. tarentolae) was analysed by Mass-Spectrometry and conserved candidate antigens were searched in the complete dataset. A total of 52 vaccine antigen candidates were selected, including 28 previously described vaccine candidates, and an additional 24 new candidates discovered through a reverse vaccinology approach.In silico HLA-I and –II epitope binding prediction analysis was performed on all selected vaccine antigens, with world coverage regarding HLA restriction. To select the best epitopes, an automated R script was developed in-house, according to strict rational criteria. From thousands of potential epitopes, the automated script, in combination with optimal IC50, homology to host and solubility properties, allowed us to select 50 class I and 24 class II epitopes, synthesized as individual peptides. In vitro toxicity assays showed these selected peptides are non-toxic to cells.The peptides’ immunogenicity was evaluated using immunoscreening assays with immune cells from human donors, allowing for the validation of in silico epitope predictions and selection, and the assessment of the peptide’s immunogenicity and prophylactic potential. Healed individuals, which had active infection and received treatment, possess Leishmania-specific memory responses and are resistant to reinfection, being considered the gold standard of protective immunity. On the other hand, the naive population is extremely important to include in the experimental validation step since it is the target population to vaccinate with a prophylactic vaccine. Importantly, a minimum specific T-cell precursor frequency is needed to induce long-lasting memory protective responses. Furthermore, there is also a positive correlation between immunodominant epitopes and a high frequency of specific T-cell precursors. Peptides able to induce Th1 and/or cytotoxic immune responses in both background are promising candidates for a vaccine formulation. Altogether,experimental validation exclusively in human samples will provide us a very strong base for a vaccine formulation and allow to accelerate translation to the field.Results show Leishmania-specific peptides successfully induce IFN-γ production by total PBMC from healed donors, and by specific T cells amplified from the naïve repertoire. Preliminary evidence exists for peptides which are immunogenic in both immune backgrounds (eight HLA-class I 9-mer peptides and five class II 15-mer peptides) which are, for now, the most promising candidates to advance for the multi-epitope peptide design.Through the combination of proteomic analysis and in silico tools, promising peptide candidates were swiftly identified and the secretome was further established as an optimal starting point for vaccine development. The proposed vaccine preclinical development pipeline delivered a rapid selection of immunogenic peptides, providing a powerful approach to fast-track the deployment of an effective pan-specific vaccine against Leishmaniases
APA, Harvard, Vancouver, ISO, and other styles
2

Létourneau, Sven C. "HIV-1 vaccine development." Thesis, University of Oxford, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.442825.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Thompson, Fiona Mary. "Malaria immunology and vaccine development." Thesis, University of Southampton, 2008. https://eprints.soton.ac.uk/67626/.

Full text
Abstract:
This thesis describes work undertaken by the author at the University of Oxford. It begins by providing an introduction to malaria infection and pathophysiology, and a review of the latest attempts to produce an effective malaria vaccine. It goes on to describe the rationale behind the vaccines developed by the University of Oxford and others. A brief introduction to the process of planning and carrying out clinical trials of vaccines is then provided, and is followed by chapters describing two clinical trials, designed to test the safety, immunogenicity and then efficacy of candidate malaria vaccines. These trials were performed in Oxford, to examine two different vaccination approaches. The first intended to broaden the specificity of the vaccine induced immune response, by providing multiple antigens in one vaccine, aiming thereby to improve protection from malaria infection. The second regimen used a combination vaccine intending to induce both humoral and cellular immunity simultaneously, thereby providing enhanced efficacy against malaria infection. Neither approach was sufficient to provide protection from infection in the challenge studies described; however, some impact on the disease was detected in the second study. This is examined in detail. The laboratory work described studies background immune responses (both cellular and humoral) to vaccine antigens in a malaria exposed population, intended to support the inclusion of these antigens in the multi-antigen vaccine. The remaining chapters describe work in parasite life cycle modelling, undertaken to aid interpretation of results of these clinical trials, and finally an examination of the clinical course of malaria in the control volunteers who have taken part in the many challenge studies conducted in Oxford.
APA, Harvard, Vancouver, ISO, and other styles
4

Busch, Marc Gregory. "Evaluation of different SIV plasmid DNA vaccines : a model for HIV vaccine development /." For electronic version search Digital dissertations database. Restricted to UC campuses. Access is free to UC campus dissertations, 2004. http://uclibs.org/PID/11984.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Brune, Karl Dietrich. "Engineering modular platforms for rapid vaccine development." Thesis, University of Oxford, 2016. https://ora.ox.ac.uk/objects/uuid:41d57165-6e7c-4ca7-8025-b5ec31794c8c.

Full text
Abstract:
Vaccines have saved more lives than any other medical intervention. Recombinant vaccines provide unmatched safety profiles, but at the expense of reduced immunogenicity. Virus-like particles (VLPs) resemble viruses in size, shape and repetitive arrangement but are devoid of pathogenic genetic material and therefore safe. Poor immunogens can be rendered immunogenic by display on VLPs. Successfully decorating VLPs is still a major challenge. Genetic fusion or chemical modification is often time-consuming and can lead to misassembly or misfolding, which obstructs generation of the desired immune response. SpyCatcher is a genetically encodable protein, previously engineered to form a covalent isopeptide bond to its peptide-partner SpyTag. Presented in this thesis are SpyCatcher-VLPs, based on the fusion of SpyCatcher to the bacteriophage VLP AP205. SpyCatcher- VLPs can be conveniently conjugated with SpyTag fused antigens, simply by mixing. I demonstrate the modularity of this approach by covalently linking several complex, cysteine-rich malarial antigens to SpyCatcher-VLPs, such as the transmission-blocking antigen Pfs25 and the blood-stage antigen CIDR. A single administration of Pfs25-SpyTag conjugated to SpyCatcher-VLPs induced potent antibody generation against Pfs25, even in the absence of adjuvant. Anti-Pfs25 antibodies induced by this platform conveyed potent transmission-blocking activity in the mosquito vector. The thesis further demonstrates the feasibility of more complex Catcher-nanoparticle architectures. The previously engineered SnoopCatcher covalently reacts with SnoopTag peptide and is orthogonal to the SpyCatcher / SpyTag pair. IMX313 is an engineered chimera of the multimerization domain of chicken complement inhibitor C4-binding protein. This work describes fusion of SnoopCatcher and SpyCatcher to IMX313, which yields independently addressable Catcher-moieties on a single IMX313 nanoparticle. Display of two antigens on one particle may enable single-particle, multi-disease vaccines as well as multi-stage vaccines to tackle immune evasion of parasites. The platforms presented should accelerate and enhance vaccine development and may create opportunities for imaging and metabolic engineering.
APA, Harvard, Vancouver, ISO, and other styles
6

Flock, Margareta. "Development of a vaccine against strangles /." Stockholm, 2005. http://diss.kib.ki.se/2005/91-7140-500-3/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Poobalane, Saravanane. "Aeromonas hydrophila vaccine development using immunoproteomics." Thesis, University of Stirling, 2007. http://hdl.handle.net/1893/195.

Full text
Abstract:
Aeromonas hydrophila is an opportunistic pathogen that causes a wide range of symptoms and diseases in fish. Development of a commercial vaccine has been problematic due to the heterogenicity between isolates of A. hydrophila. A new approach using immunoproteomics was used in this study to try to develop a vaccine that would protect against a wide range of A. hydrophila strains. The virulence of 14 isolates of A. hydrophila from different geographical regions was determined in common carp (Cyprinus carpio) indicating that 6 isolates were virulent, while 8 isolates were avirulent. Expression of cellular and extracellular products (ECP) of six of these isolates (4 virulent and 2 avirulent isolates) were examined following culture of the bacterium in vitro, in tryptic soy broth, and in vivo, in dialysis tubing placed within the peritoneal cavity of carp. Two types of molecular weight cut off tubes (25 and 100 kDa) were used for the implants. Whole cell (WC), outer membrane protein (OMP) and ECPs of the bacteria grown in vitro and in vivo were analysed by 1 dimensional sodium dodecyl sulphate-polyacrylamide gel electrophoresis (1D SDS-PAGE). Additionally, 2D SDS-PAGE was used to analyse WC preparations of A. hydrophila grown in vitro and in vivo. The production of unique proteins and up and down-regulation of protein expression were observed in all the preparations of bacteria grown in vitro and in vivo. Unique bands were seen in the 1D SDS-PAGE at 58 and 55 kDa for WC and OMP preparations, respectively, for all the isolates cultured in vivo. Bands of increased intensity were observed at 70, 55, 50 and 25 kDa with WC preparations for the virulent isolates cultured in vivo. Analysis of WC preparations by 2D SDS-PAGE indicated differences in the expression of spots between bacteria cultured in vitro and in vivo. A number of unique spots, mostly between 30 and 80 kDa with pI values ranging from 5.0-6.0 were observed in the bacteria grown in vivo. The protein profiles of different preparations (WC, OMP, ECP) of bacteria cultured in vitro and in vivo were screened by 1D Western blot using antibodies from carp artificially infected with different isolates of A. hydrophila to identify potential vaccine candidates. The WC preparations of A. hydrophila (T4 isolate) grown in vitro were also analysed by 2D Western blot. A 50 kDa protein of A. hydrophila was found to be the most immunogenic molecule in both WC and OMP of bacteria grown both in vitro and in vivo. The protection efficacy of this protein was determined in goldfish by vaccinating fish with electro-eluted 50 kDa protein then challenging the fish with A. hydrophila. Fish were also passively immunised with fish sera raised to the 50 kDa protein and then challenged. The relative percentage survival (RPS) was 67 % in the vaccination trial, while the results were inconclusive for the passive immunisation trial. The 50 kDa protein was confirmed to be the S-layer protein of A. hydrophila following identification using matrix-assisted laser desorption ionisation time-of-flight mass spectrometry (MALDI-TOF MS). Recombinant S-layer protein was then produced and the cross-protection efficacy of this protein against six virulent isolates of A. hydrophila was confirmed in a large scale vaccination trial using carp. The RPS value for the 6 isolates of A. hydrophila ranged from between 56 and 87 %. The results of this project suggest that the immunogenic S-layer protein of A. hydrophila could be used as a common antigen to protect fish against infection by different isolates of this pathogenic bacterium.
APA, Harvard, Vancouver, ISO, and other styles
8

Beard, Jody. "Early development of a hookworm vaccine." Thesis, University of Nottingham, 2004. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.416306.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Aguilar, Roberto III. "Development of A Testicular Cancer Vaccine." Cleveland State University / OhioLINK, 2016. http://rave.ohiolink.edu/etdc/view?acc_num=csu1461270103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Tarcha, Eric J. "Application of Immunoproteomics and Bioinformatics to coccidioidomycosis Vaccinology." University of Toledo Health Science Campus / OhioLINK, 2006. http://rave.ohiolink.edu/etdc/view?acc_num=mco1154441973.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Vaccine development"

1

Plotkin, Stanley A., ed. History of Vaccine Development. Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-1339-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

E, Kaufmann S. H., ed. Concepts in vaccine development. Walter de Gruyter, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

service), SpringerLink (Online, ed. History of Vaccine Development. Springer Science+Business Media, LLC, 2011.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Koff, Wayne C., and Howard R. Six. Vaccine Research and Development. CRC Press, 2024. http://dx.doi.org/10.1201/9781003573838.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

L, Hoffman Stephen, ed. Malaria vaccine development: A multi-immune response approach. ASM Press, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Lukashevich, Igor S., and Haval Shirwan, eds. Novel Technologies for Vaccine Development. Springer Vienna, 2014. http://dx.doi.org/10.1007/978-3-7091-1818-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Committee on Issues and Priorities for New Vaccine Development. New vaccine development: establishing priorities. National Academy P, 1985.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Vanniasinkam, Thiru, Suresh K. Tikoo, and Siba K. Samal, eds. Viral Vectors in Veterinary Vaccine Development. Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-51927-8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bagnoli, Fabio, Giuseppe Del Giudice, Sanjay K. Phogat, and Rino Rappuoli, eds. Human Challenge Studies for Vaccine Development. Springer Nature Switzerland, 2024. http://dx.doi.org/10.1007/978-3-031-63118-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Rappuoli, Rino, and Fabio Bagnoli. Advanced vaccine research: Methods for the decade of vaccines. Caister Academic Press, 2015.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Vaccine development"

1

Karanikolas, Nicholas, and Jonathan Coleman. "Vaccine Development." In Bladder Cancer. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-59745-417-9_28.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Blanchard, Thomas G., and Steven J. Czinn. "Vaccine Development." In Helicobacter pylori Infection and Immunity. Springer US, 2002. http://dx.doi.org/10.1007/978-1-4615-0681-2_15.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Georgiev, Vassil St. "Vaccine Development." In National Institute of Allergy and Infectious Diseases, NIH. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-297-1_35.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Healer, Julie, and Alan F. Cowman. "Vaccine Development." In Molecular Parasitology. Springer Vienna, 2016. http://dx.doi.org/10.1007/978-3-7091-1416-2_16.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Poolman, J. "Vaccine development." In Neisseriae 1990, edited by Mark Achtman, Peter Kohl, Christian Marchal, Giovanna Morelli, Andrea Seiler, and Burghard Thiesen. De Gruyter, 1991. http://dx.doi.org/10.1515/9783110867787-032.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Masci, Joseph R., and Elizabeth Bass. "Vaccine Development." In Ebola. CRC Press, 2017. http://dx.doi.org/10.1201/9781315119854-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

de Carvalho Clímaco, Marianna, Lucas Kraemer, and Ricardo Toshio Fujiwara. "Vaccine Development for Human Leishmaniasis." In Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges. Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24355-4_14.

Full text
Abstract:
AbstractThe development of vaccines for human leishmaniasis is one of the most important approaches for effectively controlling and/or eradicating the several forms of the disease. Based on the knowledge obtained from the practice of leishmanization and its protective immune response, several strategies have been used to develop vaccines against Leishmania species, such as the use of whole killed and attenuated parasites, recombinant proteins, and DNA vaccines. An ideal vaccine should be safe, effective, and immunogenic. Although several candidates have achieved safety and some level of effectiveness, the current challenge in the development of prophylactic vaccines is to achieve long-lasting immune protection by generating a robust and irreversible Th1 adaptive immune response in the host, with rapid recruitment of memory and effectors T cells at key acute points of infection. However, despite all efforts over the years, due to the antigenic diversity of the parasite and the complexity of the host’s immune response, human vaccine trials have been disappointing in mediating long-term immunity against sandfly-delivered infection. Therefore, more investments in this field should be carried out to translate preclinical findings from mice to humans through effective vaccine development strategies.
APA, Harvard, Vancouver, ISO, and other styles
8

Rajaram, Sankarasubramanian, Pirada Suphaphiphat, and Yingxia Wen. "Chapter 8. Cell Culture-based Influenza Vaccine Development." In Vaccine Development. Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781839162572-00178.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Harris, Shannon L., and Peter C. Giardina. "Chapter 6. High-throughput Assays for Clinical Development." In Vaccine Development. Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781839162572-00132.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Paschall, Amy V., and Fikri Y. Avci. "Chapter 5. Pathogenesis and Immunity of SARS-CoV-2 and Vaccination Programs Against COVID-19." In Vaccine Development. Royal Society of Chemistry, 2022. http://dx.doi.org/10.1039/9781839162572-00112.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Vaccine development"

1

Malpani, Molika, and Umesh Telrandhe. "AI-powered Advancements in Drug Discovery and Vaccine Development to combat viral threats." In 2024 International Conference on Healthcare Innovations, Software and Engineering Technologies (HISET). IEEE, 2024. http://dx.doi.org/10.1109/hiset61796.2024.00097.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Vandu-Kwabe, Waseve, Maryam Aminu, and Helen I. Inabo. "Factors Affecting Immunity Level to Hepatitis B Vaccine in Some Parts of Nigeria." In 2024 International Conference on Science, Engineering and Business for Driving Sustainable Development Goals (SEB4SDG). IEEE, 2024. http://dx.doi.org/10.1109/seb4sdg60871.2024.10629971.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Hasanat, Raisa T., Nafees Mansoor, Nabeel Mohammed, Mohammad S. Rahman, Sifat Momen, and Mirza Rasheduzzaman. "Design and Development of an IoT Based Smart Vaccine Carrier and Real-Time Monitoring System." In 2024 6th International Conference on Sustainable Technologies for Industry 5.0 (STI). IEEE, 2024. https://doi.org/10.1109/sti64222.2024.10951133.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Eraghi, Vida. "Vaccine Development against Paratuberculosis." In Socratic Lectures 8. University of Lubljana Press, 2023. http://dx.doi.org/10.55295/psl.2023.i2.

Full text
Abstract:
Paratuberculosis or Johne’s disease (JD) is a chronic granulomatous enteritis affecting ruminants worldwide. It is caused by Mycobacterium avium subsp. paratuberculosis (MAP) and the rate of prevalence is increasing. Based on high economic impacts and public health concern, vaccine development against paratuberculosis is very essential. There is a lot of research articles about finding the best management approach for eradicating MAP, and also finding an ideal vaccine against the disease. But unfortunately, until now, there is no ideal management approach against the disease because we don’t have any ideal vaccine against it. This mini review discuses about management strategies with the focus on researches about various types of vaccines against JD. Keywords: Mycobacterium avium subsp. paratuberculosis (MAP); Vaccine; Johne’s disease; Paratuberculosis; Control
APA, Harvard, Vancouver, ISO, and other styles
5

Krishnakumar, D., and K. S. Jaganathan. "Development of nasal HPV vaccine formulations." In 16th Annual International Conference RGCON. Thieme Medical and Scientific Publishers Private Ltd., 2016. http://dx.doi.org/10.1055/s-0039-1685403.

Full text
Abstract:
Cervical cancer is the second most cancer in women worldwide with over 500000 new cases and 275000 deaths being registered every year. With nearly 73000 women dying every year, India now tops the world in cervical cancer deaths. India represents 26.4% of all women dying of cervical cancer globally. Cervical cancer estimated to be responsible for about 5% of human cancers worldwide. Currently available vaccines may not provide complete protection against all HPV types as the protection is primarily type specific. Furthermore, the available vaccines are delivered via intramuscular route and require three doses and require cold chain supply which increases the cost of vaccine. Therefore a single dose vaccine delivered via non-invasive route (nasal) that protects against multiple HPV types would be a cost effective and better alternative to the currently available HPV vaccines. The main objective of this study was to prepare HPV antigen loaded poly (lactic-co-glycolic acid) (PLGA) and Tri Methyl Chitosan (TMC) coated PLGA microparticles and compare their efficacy as nasal vaccine. The developed formulations were characterized for size, zeta potential, entrapment efficiency, mucin adsorption ability, in vitro and in vivo studies. PLGA microparticles demonstrated negative zeta potential whereas PLGA-TMC microparticles showed higher positive zeta potential. The protein loading efficiency was found as above 80%. Results indicated that PLGA-TMC microparticles demonstrated substantially higher mucin adsorption when compared to PLGA microparticles. HPV antigen encapsulated in PLGA-TMC particles elicited a significantly higher secretory (IgA) immune response compared to that encapsulated in PLGA particles. Present study demonstrates that PLGA-TMC microparticles with specific size range can be a better carrier adjuvant for nasal subunit vaccines. Surface modified PLGA microparticles proved great potential as a nasal delivery system for HPV infections where systemic and mucosal responses are necessary particularly in conditions after viral pathogens invade the host through the mucosal surface.
APA, Harvard, Vancouver, ISO, and other styles
6

Kumar, Vishnu, Vijay Srinivasan, and Soundar Kumara. "Towards Smart Vaccine Manufacturing: A Preliminary Study During COVID-19." In ASME 2021 International Mechanical Engineering Congress and Exposition. American Society of Mechanical Engineers, 2021. http://dx.doi.org/10.1115/imece2021-70516.

Full text
Abstract:
Abstract Biopharmaceutical community is devising modern techniques to boost the development, production, and distribution of COVID-19 vaccines in large scale with tremendous speed. This has shifted the focus towards smart manufacturing of vaccines through vaccine platforms. Vaccine platforms have great potential to rapidly generate new vaccines and can overcome the challenges of the traditional vaccine manufacturing approach without compromising on safety and efficacy. This preliminary study compares the traditional and modern vaccine manufacturing techniques, reviews COVID-19 vaccine manufacturing scenarios, and presents a framework to critique on the smartness of the novel platform-based COVID-19 vaccine development and manufacturing.
APA, Harvard, Vancouver, ISO, and other styles
7

Ermakova, M. Yu, S. V. Ivanov, A. A. Shishova, and A. A. Sinyugina. "OBTAINING MONOCLONAL ANTIBODIES TO POLIOVIRUS STRAINS SABIN FOR THE DEVELOPMENT OF AN ELISA TEST SYSTEM." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-182.

Full text
Abstract:
Poliomyelitis is an acute infectious disease caused by the poliovirus. Two types of vaccines are used to prevent poliomyelitis: oral (live) polio vaccine and inactivated polio vaccine [1]. To test the immunogenicity of vaccine preparations, there is a need to develop a highly specific ELISA test system that will allow for intratype differentiation of polioviruses.
APA, Harvard, Vancouver, ISO, and other styles
8

Asif Rasheed, Muhammad, Farrukh Jamil, and Kainaat Shoukat. "Vaccine Development for Newcastle Disease Virus in Poultry : Vaccine Development for NDV." In 2022 7th International Conference on Intelligent Informatics and Biomedical Sciences (ICIIBMS). IEEE, 2022. http://dx.doi.org/10.1109/iciibms55689.2022.9971533.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Zhou, Luoyi Zhou, Ashenafi Kiros Wubshet, Jiangrong Zhang, et al. "The mRNA Vaccine Expressing Single and Fused Structural Proteins of Porcine Reproductive and Respiratory Syndrome Induces Strong Cellular and Humoral Immune Responses in BalB/C Mice." In БИОТЕХНОЛОГИЯ: НАУЧНЫЕ ИССЛЕДОВАНИЯ И СВЯЗЬ С ПРОИЗВОДСТВОМ. Всероссийский научно-исследовательский и технологический институт биологической промышленности, 2024. https://doi.org/10.47804/978-5-89904-038-2-2024-83-89.

Full text
Abstract:
Porcine reproductive and respiratory syndrome (PRRS) is a viral disease that causes significant economic losses. The development of a new and effective vaccine is key to the spread of the virus within the farm. Several vaccinations against PRRSV have been carried out using both traditional and alternative vaccines. Unfortunately, there is currently no vaccine that can completely stop this disease. Thus, our study aimed to develop an mRNA vaccine using antigens based on individual or fused PRRSV structural proteins. In this study, the nucleotide sequence of immunogenic mRNA was determined taking into account the antigenicity of the structural proteins and the stability of the spatial structure. Purified GP5 protein served as a reference antigen for immunological evaluation. The results obtained showed that mRNA vaccines can significantly stimulate the cellular and humoral immune response. In particular, GP5-mRNA showed an immune response similar to that of a commercially available vaccine when administered in high doses.
APA, Harvard, Vancouver, ISO, and other styles
10

GIRARD, MARC P. "VACCINE DEVELOPMENT: A MAJOR CHALLENGE." In International Seminar on Nuclear War and Planetary Emergencies 34th Session. WORLD SCIENTIFIC, 2006. http://dx.doi.org/10.1142/9789812773890_0019.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Vaccine development"

1

Bymark, Jeff. SARS-CoV-2 Vaccine Development. Iowa State University, 2021. http://dx.doi.org/10.31274/cc-20240624-1255.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Ivy, John M. Development of Dengue Vaccine, Phase 1. Defense Technical Information Center, 1987. http://dx.doi.org/10.21236/ada260281.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Clements, John D., Lucy Freytag, Vijay John, and Tarun Mandal. Tulane/Xavier Vaccine Development/Engineering Project. Defense Technical Information Center, 2012. http://dx.doi.org/10.21236/ada614939.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Clements, John D., Lucy Freytag, Vijay John, and Tarun Mandal. Tulane/Xavier Vaccine Development/Engineering Project. Defense Technical Information Center, 2008. http://dx.doi.org/10.21236/ada482303.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Konakanchi, Lakshmi sravya. Vaccine Development for Respiratory Syncytial Virus. Iowa State University, 2020. http://dx.doi.org/10.31274/cc-20240624-1577.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

McKenzie, Ian. Vaccine Development Against Novel Breast Cancer Antigens. Defense Technical Information Center, 2001. http://dx.doi.org/10.21236/ada404639.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lemon, Stanley M. New Approaches to Hepatitis A Vaccine Development. Defense Technical Information Center, 1992. http://dx.doi.org/10.21236/ada249594.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lemon, Stanley M. New Approaches to Hepatitis A Vaccine Development. Defense Technical Information Center, 1994. http://dx.doi.org/10.21236/ada298648.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Reinhold, Vernon N. 'Coxiella Burnetii' Vaccine Development: Lipopolysaccharide Structural Analysis. Defense Technical Information Center, 1991. http://dx.doi.org/10.21236/ada233705.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lemon, Stanley M. New Approaches to Hepatitis A Vaccine Development. Defense Technical Information Center, 1991. http://dx.doi.org/10.21236/ada237161.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Vaccine development' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography